Department of Urology, Centro Hospitalar Universitário do São João, Porto, Portugal.
National Hospital for Neurology and Neurosurgery, University College London Hospitals Foundation Trust, University College London, London, UK.
Eur Urol Focus. 2023 Jan;9(1):172-177. doi: 10.1016/j.euf.2022.07.007. Epub 2022 Aug 6.
Despite the high prevalence of a myofascial pain component in chronic pelvic pain (CPP) syndromes, awareness and management of this component are lacking among health care providers.
To summarize the current state of the art for the management of myofascial pain in chronic primary pelvic pain syndromes (CPPPS) according to scientific research and input from experts from the European Association of Urology (EAU) guidelines panel on CPP.
A narrative review was undertaken using three sources: (1) information in the EAU guidelines on CPP; (2) information retrieved from the literature on research published in the past 3 yr on myofascial pelvic pain; and (3) expert opinion from panel members.
Studies confirm a high prevalence of a myofascial pain component in CPPPS. Examination of the pelvic floor muscles should follow published recommendations to standardize findings and disseminate the procedure. Treatment of pelvic floor muscle dysfunction and pain in the context of CPP was found to contribute to CPP control and is feasible via different physiotherapy techniques. A multidisciplinary approach is the most effective.
Despite its high prevalence, the myofascial component of CPP has been underevaluated and undertreated to date. Myofascial pain must be assessed in all patients with CPPPS. Treatment of the myofascial pain component is relevant for global treatment success. Further studies are imperative to reinforce and better define the role of each physiotherapy technique in CPPPS.
Pain and inflammation of the body's muscle and soft tissues (myofascial pain) frequently occurs in pelvic pain syndromes. Its presence must be evaluated to optimize management for each patient. If diagnosed, myofascial pain should be treated.
尽管在慢性盆腔疼痛(CPP)综合征中存在很高比例的肌筋膜疼痛成分,但医疗保健提供者对此成分的认识和管理仍有所欠缺。
根据科学研究和欧洲泌尿外科学会(EAU)CPP 指南小组专家的意见,总结慢性原发性盆腔疼痛综合征(CPPPS)中肌筋膜疼痛管理的最新进展。
采用三种来源进行叙述性综述:(1)EAU CPP 指南中的信息;(2)过去 3 年中关于肌筋膜盆腔疼痛研究的文献中检索到的信息;(3)小组成员的专家意见。
研究证实 CPPPS 中存在很高比例的肌筋膜疼痛成分。对盆底肌肉的检查应遵循已发表的建议,以规范发现并传播该程序。在 CPP 的背景下治疗盆底肌肉功能障碍和疼痛被发现有助于 CPP 的控制,并且通过不同的物理治疗技术是可行的。多学科方法是最有效的。
尽管肌筋膜成分在 CPP 中的患病率很高,但迄今为止,对其的评估和治疗仍不足。所有 CPPPS 患者均应评估肌筋膜成分。治疗肌筋膜疼痛成分对整体治疗成功至关重要。需要进一步研究来加强和更好地定义每种物理治疗技术在 CPPPS 中的作用。
身体肌肉和软组织(肌筋膜疼痛)的疼痛和炎症经常发生在盆腔疼痛综合征中。为了优化每位患者的管理,必须评估其存在情况。如果诊断出肌筋膜疼痛,应进行治疗。